SRF |
cornea |
Dstn1-corn mutant |
Permissive
Robust
|
Mus musculus |
GSE54209
...
|
MA0083.3
|
SRF |
NIH 3T3 (embryonic fibroblasts) |
Latrunculin B 0.3uM |
Permissive
Robust
|
Mus musculus |
GSE45888
...
|
MA0083.3
|
SRF |
NIH 3T3 (embryonic fibroblasts) |
U0126 10uM |
Permissive
Robust
|
Mus musculus |
GSE45888
...
|
MA0083.3
|
SRF |
BMDM (bone marrow-derived macrophages) |
Lipid A stimulation for 0 minutes |
Permissive
Robust
|
Mus musculus |
GSE67343
...
|
MA0083.3
|
SRF |
BMDM (bone marrow-derived macrophages) |
Lipid A stimulation for 15 minutes |
Permissive
Robust
|
Mus musculus |
GSE67343
...
|
MA0083.3
|
SRF |
BMDM (bone marrow-derived macrophages) |
Lipid A stimulation for 60 minutes |
Permissive
Robust
|
Mus musculus |
GSE67343
...
|
MA0083.3
|
SRF |
BMDM (bone marrow-derived macrophages) |
Lipid A stimulation for 120 minutes |
Permissive
Robust
|
Mus musculus |
GSE67343
...
|
MA0083.3
|
SRF |
embryonic fibroblasts |
after 12 min heat shock |
Permissive
|
Mus musculus |
GSE71708
...
|
MA0083.3
|
SRF |
embryonic fibroblasts |
after 60 min heat shock |
Permissive
|
Mus musculus |
GSE71708
...
|
MA0083.3
|
SRF |
embryonic fibroblasts |
12-O-tetradecanoyl phorbol-13-acetate (Sigma TPA, 50 ng/ml) for 30 minutes |
Permissive
Robust
|
Mus musculus |
GSE75667
...
|
MA0083.3
|
SRF |
embryonic fibroblasts |
TCF KO |
Permissive
Robust
|
Mus musculus |
GSE75667
...
|
MA0083.3
|
SRF |
embryonic fibroblasts |
TCF KO; 12-O-tetradecanoyl phorbol-13-acetate (Sigma TPA, 50 ng/ml) for 30 minutes |
Permissive
Robust
|
Mus musculus |
GSE75667
...
|
MA0083.3
|
SRF |
A-673 clone Asp114 (Ewing sarcoma) |
no doxycycline, serum-induction |
Permissive
|
Homo sapiens |
GSE92738
...
|
MA0083.3
|
SRF |
primary vascular smooth muscle cell (C57BL/6 mice) |
Passage: p1 |
Permissive
Robust
|
Mus musculus |
GSE112417
...
|
MA0083.3
|
SRF |
primary vascular smooth muscle cell (C57BL/6 mice) |
Passage: p10 |
Permissive
Robust
|
Mus musculus |
GSE112417
...
|
MA0083.3
|
SRF |
primary vascular smooth muscle cell (C57BL/6 mice) |
Treatment: infected with shNT for 3 days |
Permissive
Robust
|
Mus musculus |
GSE112417
...
|
MA0083.3
|
SRF |
primary vascular smooth muscle cell (C57BL/6 mice) |
Treatment: infected with shNT for 3 days |
Permissive
Robust
|
Mus musculus |
GSE112417
...
|
MA0083.3
|
SRF |
primary vascular smooth muscle cell (C57BL/6 mice) |
Treatment: infected with sh2AZ for 3 days |
Permissive
|
Mus musculus |
GSE112417
...
|
MA0083.3
|
SRF |
primary vascular smooth muscle cell (C57BL/6 mice) |
Treatment: infected with sh2AZ for 3 days |
Permissive
Robust
|
Mus musculus |
GSE112417
...
|
MA0083.3
|
SRF |
differentiated neural progenitor cells |
Source: Neural progenitor cells expressing no ectopic gene |
Permissive
Robust
|
Mus musculus |
GSE106319
...
|
MA0083.3
|
SRF |
differentiated neural progenitor cells |
Treatment: transgene of Srf was introduced retrovirally Source: Neural progenitor cells overexpressing Srf |
Permissive
Robust
|
Mus musculus |
GSE106319
...
|
MA0083.3
|
SRF |
fetal liver |
Source: Hepatoblasts (expressing no ectopic gene) |
Permissive
Robust
|
Mus musculus |
GSE106319
...
|
MA0083.3
|
SRF |
HEL (Erythro Leukemia) |
Treatment: No treatment, no TPA Source: HEL-iMKL1 cells |
Permissive
Robust
|
Homo sapiens |
GSE112265
...
|
MA0083.3
|
SRF |
HEL (Erythro Leukemia) |
Treatment: No treatment, no TPA Source: HEL-iMKL1 cells |
Permissive
Robust
|
Homo sapiens |
GSE112265
...
|
MA0083.3
|
SRF |
HEL (Erythro Leukemia) |
Treatment: Treated with 10ng/ml Dox for 24 hours Source: HEL-iMKL1 cells |
Permissive
Robust
|
Homo sapiens |
GSE112265
...
|
MA0083.3
|
SRF |
HEL (Erythro Leukemia) |
Treatment: Treated with 10ng/ml Dox for 24 hours Source: HEL-iMKL1 cells |
Permissive
Robust
|
Homo sapiens |
GSE112265
...
|
MA0083.3
|
SRF |
HEL (Erythro Leukemia) |
Treatment: Treated with 15nM TPA for 24 hours Source: HEL-iMKL1 cells |
Permissive
Robust
|
Homo sapiens |
GSE112265
...
|
MA0083.3
|
SRF |
HEL (Erythro Leukemia) |
Treatment: Treated with 15nM TPA for 24 hours Source: HEL-iMKL1 cells |
Permissive
Robust
|
Homo sapiens |
GSE112265
...
|
MA0083.3
|
SRF |
HEL (Erythro Leukemia) |
Treatment: Treated with 10ng/ml Dox & 15nM TPA for 24 horus Genotype: mkl overexpressed |
Permissive
Robust
|
Homo sapiens |
GSE112265
...
|
MA0083.3
|
SRF |
HEL (Erythro Leukemia) |
Treatment: Treated with 10ng/ml Dox & 15nM TPA for 24 horus Genotype: mkl overexpressed |
Permissive
Robust
|
Homo sapiens |
GSE112265
...
|
MA0083.3
|
SRF |
10T1/2 |
Treatment: sictrl; Background cell line: C3H/HeN; |
Permissive
Robust
|
Mus musculus |
GSE40369
...
|
MA0083.3
|
SRF |
ILC2 (type 2 Innate lympoid cells) |
Treatment: siMed23; Background cell line: C3H/HeN; Genotype: knockdown Med23; |
Permissive
Robust
|
Mus musculus |
GSE40369
...
|
MA0083.3
|
SRF |
induced pluripotent stem cells |
Passage: 25 days; Genotype: Overexpression SRF; Treatment: pMSCV mediated virus; |
Permissive
Robust
|
Mus musculus |
GSE120399
...
|
MA0083.3
|
SRF |
induced pluripotent stem cells |
Passage: 25 days; Genotype: Overexpression SRF, caMKL1 blocked; Treatment: pMSCV mediated virus; |
Permissive
Robust
|
Mus musculus |
GSE120399
...
|
MA0083.3
|
SRF |
induced pluripotent stem cells |
Passage: 25 days; Genotype: Overexpression SRF; Treatment: pMSCV mediated virus; |
Permissive
Robust
|
Mus musculus |
GSE120399
...
|
MA0083.3
|
SRF |
induced pluripotent stem cells |
Passage: 25 days; Genotype: Overexpression SRF, caMKL1 blocked; Treatment: pMSCV mediated virus; |
Permissive
Robust
|
Mus musculus |
GSE120399
...
|
MA0083.3
|
SRF |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BGE
|
MA0083.3
|
SRF |
WA01 (H1, human embryonic stem cells) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BIV
|
MA0083.3
|
SRF |
K562 (myelogenous leukemia) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BLK
|
MA0083.3
|
SRF |
HepG2 (hepatoblastoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BLV
|
MA0083.3
|
SRF |
GM12878 (female B-cells lymphoblastoid cell line) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BMI
|
MA0083.3
|
SRF |
HCT-116 (colon carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BSC
|
MA0083.3
|
SRF |
Ishikawa (endometrial adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BTD
|
MA0083.3
|
SRF |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
ENCSR000BVA
|
MA0083.3
|
SRF |
HL-1 (cardiac muscle cells) |
|
Permissive
|
Mus musculus |
GSE19065
...
|
MA0083.3
|
SRF |
myocytes |
|
Permissive
Robust
|
Mus musculus |
ENCSR000AIM
...
|
MA0083.3
|
SRF |
HL-1 (cardiac muscle cells) |
|
Permissive
Robust
|
Mus musculus |
GSE21529
...
|
MA0083.3
|
SRF |
cornea |
|
Permissive
Robust
|
Mus musculus |
GSE54209
...
|
MA0083.3
|
SRF |
embryonic fibroblasts |
|
Permissive
|
Mus musculus |
GSE71708
...
|
MA0083.3
|
SRF |
HUES64 (embryonic stem cells) |
|
Permissive
|
Homo sapiens |
GSE61475
...
|
MA0083.3
|
SRF |
HUES64 (embryonic stem cells) |
|
Permissive
|
Homo sapiens |
GSE61475
...
|
MA0083.3
|
SRF |
HUES64 (embryonic stem cells) |
|
Permissive
|
Homo sapiens |
GSE61475
...
|
MA0083.3
|
SRF |
HUES64 (embryonic stem cells) |
|
Permissive
|
Homo sapiens |
GSE61475
...
|
MA0083.3
|
SRF |
HUES64 (embryonic stem cells) |
|
Permissive
|
Homo sapiens |
GSE61475
...
|
MA0083.3
|
SRF |
embryonic fibroblasts |
|
Permissive
Robust
|
Mus musculus |
GSE75667
...
|
MA0083.3
|
SRF |
primary vascular smooth muscle cell (C57BL/6 mice) |
|
Permissive
|
Mus musculus |
GSE112417
...
|
MA0083.3
|